Digestive Diseases and Sciences

, Volume 52, Issue 2, pp 442–450 | Cite as

A Randomized, Double-Blind, One-Week Study Comparing Effects of a Novel COX-2 Inhibitor and Naproxen on the Gastric Mucosa

  • James B. Moberly
  • Stuart I. Harris
  • Dennis S. Riff
  • James Craig Dale
  • Tara Breese
  • Patrick McLaughlin
  • Janet Lawson
  • Yaping Wan
  • Jianbo Xu
  • Kenneth E. Truitt
Original Article


CS-706 is a novel cyclooxygenase-2 (COX-2) inhibitor with potent analgesic, anti-inflammatory, and antitumor properties in animal models. This one-week, multicenter study was undertaken to assess the safety and tolerability of CS-706 and to compare the effects of CS-706 versus naproxen on acute gastrointestinal (GI) mucosal injury. Healthy men and women (n=160) without evidence of underlying gastroduodenal lesions were randomized to placebo, 100 mg CS-706 once daily, 200 mg CS-706 once daily, or 500 mg naproxen twice daily, administered for 7 days. On Day 8, subjects underwent a posttreatment upper GI endoscopy to assess development of gastroduodenal petechiae, erosions, and ulcers. Inhibition of COX-1 and COX-2 activity over the 24-hr postdose interval on Day 7 was determined in 48 subjects (12 per treatment group). CS-706 was safe and well tolerated. The extent of upper GI mucosal injury for both CS-706 dose groups was statistically significantly less than that for naproxen (P < 0.001) and was similar to placebo (P=0.615 and P=0.115 for 100 and 200 mg CS-706, respectively). No subject in placebo or either CS-706 treatment group had gastroduodenal ulcers, compared with 11 (28.2%) subjects treated with naproxen (P < 0.001). Both doses of CS-706 inhibited COX-2 activity to a similar extent as naproxen, whereas neither dose of CS-706 showed meaningful inhibition of platelet COX-1. In contrast, naproxen nearly completely inhibited COX-1 over the dosing interval. We conclude that CS-706, dosed up to 200 mg once daily, has an acute, upper GI toxicity profile similar to that of placebo and significantly superior to that of naproxen.


Cyclooxygenase Upper GI endoscopy NSAID-induced ulcers Erosions Thromboxane Prostaglandin 



The study was sponsored by Sankyo Pharma Development. We thank Mark Stiles (MDS Pharma Services Clinical Laboratory, Lincoln, Nebraska) for performing thromboxane B2 and prostaglandin E2 assays and Jennifer Scott and Strait Hicklin (SCIREX Corporation) for monitoring the study.


  1. 1.
    Cronstein BN (2002) Cyclooxygenase-2-selective inhibitors: translating pharmacology into clinical utility. Cleve Clin J Med 69(Suppl 1):SI 13–SI 19Google Scholar
  2. 2.
    Langman MJ, Weil J, Wainwright P, et al. (1994) Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343:1075–1078PubMedCrossRefGoogle Scholar
  3. 3.
    Fries JF (1991) NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 18(28):6–10Google Scholar
  4. 4.
    Simon LS, Weaver AL, Graham DY, et al. (1999) Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 282:1921–1928PubMedCrossRefGoogle Scholar
  5. 5.
    Silverstein FE, Faich G, Goldstein JL, et al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247–1255PubMedCrossRefGoogle Scholar
  6. 6.
    Goldstein JL, Correa P, Zhao WW, et al. (2001) Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 96:1019–1027PubMedCrossRefGoogle Scholar
  7. 7.
    Laine L, Harper S, Simon T, et al. (1999) A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 117:776–783PubMedCrossRefGoogle Scholar
  8. 8.
    Bresalier RS, Sandler RS, Quan H, et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092–1102PubMedCrossRefGoogle Scholar
  9. 9.
    Nussmeier NA, Whelton AA, Brown MT, et al. (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352:1081–1091PubMedCrossRefGoogle Scholar
  10. 10.
    Graham DJ, Campen D, Hui R, et al. (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365:475–481PubMedGoogle Scholar
  11. 11.
    Antman EA, DeMets D, Loscalzo J (2005) Cyclooxygenase inhibitors and cardiovascular risk. Circulation 112:759–770PubMedCrossRefGoogle Scholar
  12. 12.
    Dannenberg A, Altorki NK, Boyle JO, et al. (2001) Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2:544–551PubMedCrossRefGoogle Scholar
  13. 13.
    Cannon CP, Curtis SP, Bolognese JA, Laine L (2006) Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J 152:237–245.Google Scholar
  14. 14.
    Simon LS, Lanza FL, Lipsky PE, et al. (1998) Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arth Rheum 41:1591–1602CrossRefGoogle Scholar
  15. 15.
    Oitate M, Hirota T, Koyama K, et al. (2006) Covalent binding of radioactivity from [14C]rofecoxib, but not [14C]celecoxib or [14C]CS-706, to the arterial elastin of rats. Drug Metab Dispos 34:1417–1422Google Scholar
  16. 16.
    Kastrissios H, Rohatagi S, Moberly J, et al. (2006) Development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor. J Clin Pharm 46:537–548CrossRefGoogle Scholar
  17. 17.
    Lanza FL, Rack MF, Simon TJ, et al. (1999) Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 13:761–767PubMedCrossRefGoogle Scholar
  18. 18.
    Riendeau D, Percival MD, Brideau C, et al. (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296:558–566PubMedGoogle Scholar
  19. 19.
    Harris SI, Kuss M, Hubbard RC, Goldstein JL (2001) Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther 23:1422–1428PubMedCrossRefGoogle Scholar
  20. 20.
    Rordorf C, Kellett N, Mair S, et al. (2003) Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: a pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther 18:533–541PubMedCrossRefGoogle Scholar
  21. 21.
    Bjarnason I, Macpherson A, Rotman H, et al. (1997) A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen. Scand J Gastroenterol 32:126–130PubMedGoogle Scholar
  22. 22.
    Bombardier C, Laine L, Reicin A, et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520–1528PubMedCrossRefGoogle Scholar
  23. 23.
    Scheiman JM (2002) Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med 69(Suppl 1):SI-40–SI-46Google Scholar
  24. 24.
    Brideau C, Kargman S, Liu S, et al. (1996) A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 45:68–74PubMedCrossRefGoogle Scholar
  25. 25.
    Van Hecken A, Schwartz JI, Depre M, et al. (2000) Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 40:1109–1120PubMedGoogle Scholar
  26. 26.
    Panara MR, Renda G, Sciulli MG, et al. (1999) Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther 290:276–280PubMedGoogle Scholar
  27. 27.
    Blain H, Boileau C, Lapicque F, et al. (2002) Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Clin Pharmacol 53:255–265PubMedCrossRefGoogle Scholar
  28. 28.
    Lanza FL, Graham DY, Davis RE, Rack MF (1990) Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury. Effect of scoring method. Dig Dis Sci 35:1494–1499PubMedCrossRefGoogle Scholar
  29. 29.
    Lanza F, Rack MF, Lynn M, et al. (1987) An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. J Rheumatol 14:338–341PubMedGoogle Scholar

Copyright information

© Springer Science&#x002B;Business Media, Inc. 2006

Authors and Affiliations

  • James B. Moberly
    • 1
  • Stuart I. Harris
    • 2
  • Dennis S. Riff
    • 3
  • James Craig Dale
    • 4
  • Tara Breese
    • 4
  • Patrick McLaughlin
    • 3
  • Janet Lawson
    • 4
  • Yaping Wan
    • 5
  • Jianbo Xu
    • 1
  • Kenneth E. Truitt
    • 1
  1. 1.Daiichi Sankyo Pharma DevelopmentEdisonUSA
  2. 2.Sea View Research, Inc.MiamiUSA
  3. 3.Advanced Clinical Research InstituteAnaheimUSA
  4. 4.SCIREX CorporationAustinUSA
  5. 5.SCIREX CorporationBloomingdaleUSA

Personalised recommendations